Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Olmesartan in Essential Hypertension
NCT00185172Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of olmesartan in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Diastolic Blood Pressure at 12 weeks. Started Jan 2002; status: completed.
02
Drugs
olmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00185172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185172.